Press Releases: 2018

Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

December 19, 2018
-- Colin Freund has joined as CEO -- Dr. Edwin De Wit appointed Head of Oncology Development -- Dr. Alan Barge appointed Chai...
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

November 13, 2018
Leiden, The Netherlands, November 13, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announce...
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

November 02, 2018
Maastricht, The Netherlands, 2nd November 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing targ...
Read more
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

October 24, 2018
Maastricht, The Netherlands, 25th October 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing uniqu...
Read more
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

October 01, 2018
--Two poster presentations highlight INT-1B3's immune-system activation and CD8+ T cell-driven anti-tumor response in addition...
Read more
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

September 10, 2018
10th September 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next...
Read more
Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing

June 26, 2018
Wädenswil, Switzerland, June 6th, 2018 Inthera Bioscience AG, a pre-clinical stage oncology company targeting the inhibition...
Read more
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing

InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

April 18, 2018
--INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pr...
Read more
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

Macrophage Pharma Appoints Dr Michael Moore as Chairman

April 11, 2018
11 April 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-gener...
Read more
Macrophage Pharma Appoints Dr Michael Moore as Chairman

MIMETAS Secures 20 Million Dollar Series B Financing

April 11, 2018
Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new produc...
Read more
MIMETAS Secures 20 Million Dollar Series B Financing

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds